Does Mounjaro Affect Fertility in Women?

The biggest misconception: Mounjaro doesn't 'cause' infertility, but the real concern runs the other way

Most searches on this topic come from a place of worry: will Mounjaro make it harder to conceive? The short answer is that there is no clinical evidence it does. Tirzepatide has not been shown to damage reproductive function in women. In fact, the conversation our prescribers have most often is the opposite one, reminding women that if weight loss improves hormonal balance and restores regular ovulation, an unplanned pregnancy becomes a real possibility.

For women with obesity-related cycle irregularity or polycystic ovary syndrome, the hormonal environment can shift considerably as weight falls. PCOS, which affects a significant proportion of women seeking weight management treatment, is closely tied to insulin resistance, and tirzepatide's dual action on GIP and GLP-1 receptors affects both appetite and blood-sugar regulation. There is early-stage research interest in whether GLP-1 receptor agonists may support reproductive outcomes in PCOS, but this sits firmly in the 'uncertain' column for now. The broader fertility picture for women on Mounjaro covers that emerging research in more detail.

The bottom line: Mounjaro does not appear to reduce fertility, and may indirectly improve it in some women. That possibility is exactly why contraception guidance matters so much.

Oral contraceptives and Mounjaro: the absorption issue prescribers flag every time

This is the safety point most women don't expect. Because Mounjaro slows gastric emptying, it can reduce how much of an oral contraceptive pill is absorbed, particularly in the first four weeks of starting treatment and in the four weeks after each dose increase. NHS England's guidance on weight-management injections explicitly advises adding a non-oral method of contraception during those windows.

This doesn't mean the pill stops working entirely, and it doesn't apply in the same way to non-oral methods like the coil, implant, patch, or injection. But if you rely solely on a combined or progestogen-only pill and you start Mounjaro, the guidance is clear: use condoms or another barrier method alongside it for those transition periods. The same principle applies every time the prescriber increases your dose, the 5mg pen, the 7.5mg pen, and so on through the schedule.

If you're unsure which contraceptive you use or whether it counts as 'oral', that is precisely the kind of thing to raise at consultation, or with your GP before you start. You can also explore the broader question of how Mounjaro affects fertility for additional context on contraception and the wash-out period.

Pregnancy, breastfeeding, and trying to conceive: what the guidance says

Mounjaro is not suitable during pregnancy. Animal studies showed developmental effects at doses relevant to human use, and there are no controlled human trials, pregnant women were excluded from the SURMOUNT programme for that reason. The manufacturer recommends stopping tirzepatide at least two months before attempting conception, to allow the medicine to clear your system before a potential pregnancy begins. If you discover you are pregnant while taking it, stop treatment and contact your GP or midwife promptly.

Breastfeeding is similarly not recommended. It is unknown whether tirzepatide passes into breast milk, and the potential risk to a nursing infant has not been studied. The NHS medicines page for tirzepatide covers both restrictions plainly, and reading it alongside the patient information leaflet inside your pen box is time well spent.

The two-month wash-out before trying to conceive is worth planning around. If you order through an online pharmacy and your plain, tracked parcel arrives with a DPD notification on your phone, the starting date of that first pen is the date your prescriber's two-month clock begins, so knowing your timeline in advance makes a real practical difference. If you're weighing up when to start or pause treatment around family planning, our support team can help you put those questions to a prescriber directly.

What we don't yet know, and why it matters

Clinical trials of tirzepatide were not designed to measure fertility outcomes. Women planning pregnancy were excluded, ovarian reserve was not measured as an endpoint, and long-term data on menstrual cycle changes are limited. Some women report cycle changes after starting GLP-1 treatment (shorter, longer, or more regular periods) but these are not yet well characterised in the literature, and it is genuinely difficult to separate the effect of the medicine from the effect of weight loss itself.

If you have a condition that affects your fertility, such as PCOS, endometriosis, or a thyroid disorder, the picture is more complex still, and if you're also wondering how treatment may affect a male partner, what we know about Mounjaro and fertility in men is worth reading alongside this. The NHS England wrap-around care guidance for weight-management injections underlines that decisions about treatment in these contexts should involve your wider clinical team, not just a weight-loss prescriber. How Mounjaro may affect fertility more broadly (including what the research gap currently looks like) is worth reading if your situation is more complicated.

The honest position: the absence of human evidence for harm is reassuring, but it is not a green light for use during pregnancy or conception attempts. If fertility is part of your picture, tell the prescriber at your consultation, and if you want a fuller overview before that conversation, our dedicated page on Mounjaro and fertility brings together the key considerations in one place. You can check your eligibility and start a free consultation with a GPhC-registered prescriber at any point.